Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181 on ClinicalTrials.gov · last registry update 2026-10-13

An unusually large phase 3: 1,205 participants, more than double the 424 typical for the stage. Due to report 25 April 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 April 2021 — 5 years so far. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ACTIVE_NOT_RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 1,205
Started: 2021-04-01
Primary completion: 2029-04-25 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)

Conditions studied

Non-alcoholic Steatohepatitis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.